Potential clinical application of anti-Müllerian hormone testing in radioiodine treatment of thyroid carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F24%3A10481277" target="_blank" >RIV/00179906:_____/24:10481277 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/24:10481277

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=8C28P7d983" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=8C28P7d983</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s13104-024-06802-y" target="_blank" >10.1186/s13104-024-06802-y</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Potential clinical application of anti-Müllerian hormone testing in radioiodine treatment of thyroid carcinoma

Popis výsledku v původním jazyce

Differentiated thyroid cancer is the most common endocrinological malignancy. Radioiodine treatment has a clear benefit in locally aggressive and metastatic cancers. There are discussions about long-term and acute adverse events.Anti-M &amp; uuml;llerian hormone is regarded as the best endocrine marker for evaluating the physiological loss of oocytes in healthy women with regard to age. The impact of radioiodine treatment on anti-M &amp; uuml;llerian hormone levels has been more significantly reported in patients over 35 years of age. About reproductive dysfunction, calculations of individual absorbed doses of radioiodine in ovaries after thyroid cancer therapy have not been performed yet. The aim of our ongoing prospective study is to determine serum anti-M &amp; uuml;llerian hormone to estimate ovarian reserve for premenopausal women treated with radioiodine and to compare anti-M &amp; uuml;llerian hormone levels before and after radioiodine treatment. Predicting radioiodine side effects by evaluating a simple serum biomarker may help to select an appropriate treatment strategy for young women planning pregnancy, specifically in the assessment of ovarian reserve and premature ovarian failure with early onset of menopause.

Název v anglickém jazyce

Potential clinical application of anti-Müllerian hormone testing in radioiodine treatment of thyroid carcinoma

Popis výsledku anglicky

Differentiated thyroid cancer is the most common endocrinological malignancy. Radioiodine treatment has a clear benefit in locally aggressive and metastatic cancers. There are discussions about long-term and acute adverse events.Anti-M &amp; uuml;llerian hormone is regarded as the best endocrine marker for evaluating the physiological loss of oocytes in healthy women with regard to age. The impact of radioiodine treatment on anti-M &amp; uuml;llerian hormone levels has been more significantly reported in patients over 35 years of age. About reproductive dysfunction, calculations of individual absorbed doses of radioiodine in ovaries after thyroid cancer therapy have not been performed yet. The aim of our ongoing prospective study is to determine serum anti-M &amp; uuml;llerian hormone to estimate ovarian reserve for premenopausal women treated with radioiodine and to compare anti-M &amp; uuml;llerian hormone levels before and after radioiodine treatment. Predicting radioiodine side effects by evaluating a simple serum biomarker may help to select an appropriate treatment strategy for young women planning pregnancy, specifically in the assessment of ovarian reserve and premature ovarian failure with early onset of menopause.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BMC Research Notes

ISSN

1756-0500

e-ISSN

1756-0500

Svazek periodika

17

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

147

Kód UT WoS článku

001230256500001

EID výsledku v databázi Scopus

2-s2.0-85194037407